Bracken Sonali J, Adami Alexander J, Rafti Ektor, Schramm Craig M, Matson Adam P
1Department of Immunology, University of Connecticut Health, 263 Farmington Avenue, Farmington, CT 06030 USA.
2Department of Pediatrics, Connecticut Children's Medical Center, Hartford, CT USA.
Clin Mol Allergy. 2018 May 18;16:13. doi: 10.1186/s12948-018-0091-x. eCollection 2018.
Allergic asthma is an inflammatory disorder of the airways that results from inappropriate production of IgE against harmless, environmental antigens. Sequestration of free IgE using humanized IgG anti-IgE is an effective therapy for asthma and other atopic disorders. However, the status of free IgE in subjects who have naturally developed immune tolerance to inhaled antigens has not been well studied.
C57BL/6 mice were sensitized and challenged with ovalbumin (OVA) for 7 days to induce allergic airway disease (AAD) or 6 weeks to induce a state of local inhalational tolerance (LIT). Serum from AAD or LIT mice, diluted to achieve equivalent levels of total OVA-specific IgE, was used to sensitize rat basophil leukemia cells for allergen-mediated degranulation. Levels of degranulation were measured in relation to serum concentrations of free IgE and IgG anti-IgE/IgE immune complexes.
Serum from AAD animals induced a greater degree of basophil degranulation than serum from LIT animals. These results correlated with higher levels of free IgE in AAD animals, whereas LIT mice demonstrated a significant increase in IgG anti-IgE/IgE immune complexes relative to their diseased counterparts.
Sequestration of free IgE by naturally occurring IgG anti-IgE may aid in the development of immune tolerance against inhaled allergens. The decrease in bioavailability of free IgE may, in turn, contribute to the overall reduction of asthma symptoms via a mechanism that mimics the therapeutic effects of humanized IgG anti-IgE.
过敏性哮喘是一种气道炎症性疾病,由针对无害环境抗原产生不适当的IgE引起。使用人源化IgG抗IgE隔离游离IgE是治疗哮喘和其他特应性疾病的有效方法。然而,对吸入性抗原自然产生免疫耐受的受试者体内游离IgE的状态尚未得到充分研究。
用卵清蛋白(OVA)对C57BL/6小鼠进行致敏和激发,持续7天以诱导过敏性气道疾病(AAD),或持续6周以诱导局部吸入耐受(LIT)状态。将来自AAD或LIT小鼠的血清稀释至总OVA特异性IgE水平相当,用于使大鼠嗜碱性粒细胞白血病细胞致敏以进行变应原介导的脱颗粒。根据游离IgE和IgG抗IgE/IgE免疫复合物的血清浓度测量脱颗粒水平。
AAD动物的血清比LIT动物的血清诱导更高程度的嗜碱性粒细胞脱颗粒。这些结果与AAD动物中较高水平的游离IgE相关,而LIT小鼠相对于患病小鼠,其IgG抗IgE/IgE免疫复合物显著增加。
天然存在的IgG抗IgE隔离游离IgE可能有助于对吸入性变应原产生免疫耐受。游离IgE生物利用度的降低反过来可能通过一种模拟人源化IgG抗IgE治疗效果的机制,导致哮喘症状总体减轻。